OBJECTIVE: To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM). PATIENTS AND METHODS: From a prospectively maintained database, we identified 47 patients seen between January 1, 1990, and August 31, 2008, with a diagnosis of AL amyloidosis that was made at least 6 months after MM diagnosis; these patients form the study group. RESULTS: Among the 47 patients, 36 developed typical features, 3 had atypical features, and 8 had an incidental finding of amyloidosis. Amyloid deposits were demonstrated in bone marrow, subcutaneous fat aspirate, or organ biopsy in 24, 19, and 12 patients, respectively. One organ was involved in 29 patients (62%), whereas 11 patients (23%) had involvement in more than one organ. At diagnosis of AL amyloidosis, treatment was changed or started in 22 patients, whereas the same treatment was continued in 21 patients, and no treatment data were available for the rest. The best hematologic response included partial response or better in 11 patients (23%) and stable disease in 18 patients (38%). Improvement in an organ was seen in 3 of the 21 evaluable patients. The median overall survival from diagnosis of AL amyloidosis was 9.1 months (95% confidence interval, 4-14). Of the 6 patients still alive, 2 underwent peripheral blood stem cell transplant, and none had cardiac involvement or involvement in more than one organ. CONCLUSION: Delayed onset of AL amyloidosis is rarely seen in patients with MM and requires a high index of suspicion for prompt diagnosis. Outcome of these patients is poor, especially in the presence of cardiac involvement.
OBJECTIVE: To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM). PATIENTS AND METHODS: From a prospectively maintained database, we identified 47 patients seen between January 1, 1990, and August 31, 2008, with a diagnosis of AL amyloidosis that was made at least 6 months after MM diagnosis; these patients form the study group. RESULTS: Among the 47 patients, 36 developed typical features, 3 had atypical features, and 8 had an incidental finding of amyloidosis. Amyloid deposits were demonstrated in bone marrow, subcutaneous fat aspirate, or organ biopsy in 24, 19, and 12 patients, respectively. One organ was involved in 29 patients (62%), whereas 11 patients (23%) had involvement in more than one organ. At diagnosis of AL amyloidosis, treatment was changed or started in 22 patients, whereas the same treatment was continued in 21 patients, and no treatment data were available for the rest. The best hematologic response included partial response or better in 11 patients (23%) and stable disease in 18 patients (38%). Improvement in an organ was seen in 3 of the 21 evaluable patients. The median overall survival from diagnosis of AL amyloidosis was 9.1 months (95% confidence interval, 4-14). Of the 6 patients still alive, 2 underwent peripheral blood stem cell transplant, and none had cardiac involvement or involvement in more than one organ. CONCLUSION: Delayed onset of AL amyloidosis is rarely seen in patients with MM and requires a high index of suspicion for prompt diagnosis. Outcome of these patients is poor, especially in the presence of cardiac involvement.
Authors: Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: Chung-Eun Ha; Nadhipuram V Bhagavan; Miki Loscalzo; Stephen K Chan; Huy V Nguyen; Carlos N Rios; Stacey A A Honda Journal: Hawaii J Med Public Health Date: 2014-06
Authors: Taxiarchis V Kourelis; Shaji K Kumar; Morie A Gertz; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Steven Zeldenrust; Nelson Leung; Robert A Kyle; Stephen Russell; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; S Vincent Rajkumar; Arleigh McCurdy; Angela Dispenzieri Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544
Authors: Jean-Baptiste Gibier; Viviane Gnemmi; François Glowacki; Eileen M Boyle; Benjamin Lopez; Evelyne MacNamara; Maxime Hoffmann; Raymond Azar; Thomas Guincestre; Franck Bourdon; Marie-Christine Copin; David Buob Journal: Mod Pathol Date: 2017-10-20 Impact factor: 7.842
Authors: Jian Guan; Shikha Mishra; Yiling Qiu; Jianru Shi; Kyle Trudeau; Guy Las; Marc Liesa; Orian S Shirihai; Lawreen H Connors; David C Seldin; Rodney H Falk; Calum A MacRae; Ronglih Liao Journal: EMBO Mol Med Date: 2014-11 Impact factor: 12.137
Authors: Seung Hyun Lee; Young Chun Ko; Jong Pil Jeong; Chan Woo Park; Seok Ho Seo; Jong Taek Kim; Dae Won Park; Cheol Min Bak; Seung Ki Moon; Shin Hyoung Jo; Se Mi Kim; Ah Lon Jung Journal: Tuberc Respir Dis (Seoul) Date: 2015-10-01